Patents by Inventor Gillian Daphne Elliott
Gillian Daphne Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7067632Abstract: Herpesviral VP22 proteins (and variants) are used to modify cell structure and cell division, by their newly found property of binding to microtubules in cells. Uses of VP22 to exploit this property include stabilisation of animal cellular microtubules in vivo and in vitro, e.g. to retard or arrest cell division or induce cell death. The microtubule binding function of VP22 can be exploited by reagent use in vitro to study microtubules or the cell cycle particularly at cell division, and pharmaceutically to retard or arrest cell division of cells such as neoplastic cells or protozoal parasite cells in vitro or in vivo.Type: GrantFiled: July 10, 2003Date of Patent: June 27, 2006Assignee: Phogen, Ltd.Inventor: Gillian Daphne Elliott
-
Publication number: 20040197346Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: ApplicationFiled: September 3, 2003Publication date: October 7, 2004Applicant: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20030219859Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.Type: ApplicationFiled: September 27, 2002Publication date: November 27, 2003Applicant: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6521455Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.Type: GrantFiled: January 31, 2001Date of Patent: February 18, 2003Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020128174Abstract: Herpesviral VP22 proteins (and variants) are used to modify cell structure and cell division, by their newly found property of binding to microtubules in cells. Uses of VP22 to exploit this property include stabilisation of animal cellular microtubules in vivo and in vitro, e.g. to retard or arrest cell division or induce cell death The microtubule binding function of VP22 can be exploited by reagent use in vitro to study microtubules or the cell cycle particularly at cell division, and pharmaceutically to retard or arrest cell division of cells such as neoplastic cells or protozoal parasite cells in vitro or in vivo.Type: ApplicationFiled: September 17, 1999Publication date: September 12, 2002Inventor: GILLIAN DAPHNE ELLIOTT
-
Publication number: 20020106378Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: ApplicationFiled: March 5, 2001Publication date: August 8, 2002Inventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020064534Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: ApplicationFiled: January 22, 2002Publication date: May 30, 2002Applicant: Phogen LimitedInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020039765Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.Type: ApplicationFiled: January 31, 2001Publication date: April 4, 2002Inventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6342229Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: GrantFiled: August 2, 1999Date of Patent: January 29, 2002Assignee: Phogen, LimitedInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20010048928Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: ApplicationFiled: August 2, 1999Publication date: December 6, 2001Inventors: PETER FRANCIS JOSEPH O'HARE, GILLIAN DAPHNE ELLIOTT
-
Patent number: 6251398Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: GrantFiled: September 13, 1999Date of Patent: June 26, 2001Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6184038Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.Type: GrantFiled: January 26, 1998Date of Patent: February 6, 2001Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6017735Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.Type: GrantFiled: January 22, 1998Date of Patent: January 25, 2000Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott